Obstetrics and gynecology:

No abstract available

No abstract available

With significant overall survival benefits reported in several phase 3 randomized clinical trials, the integration of anti-PD-1 immunotherapy with systemic chemotherapy has transformed the therapeutic landscape in advanced endometrial cancer and PD-L1+ recurrent/metastatic cervical cancer. For patients with FIGO stage III-IVA locally advanced cervical cancer, irrespective of PD-L1 status, chemoradiation plus pembrolizumab followed by maintenance pembrolizumab also confers a survival benefit. For newly diagnosed advanced ovarian cancer responding to primary systemic chemotherapy, maintenance therapy using PARP inhibitors and/or bevacizumab according to germline and somatic mutational analysis have been demonstrated to improve progression-free survival. Tumor heterogeneity, acquired drug resistance, and adverse events limit long-term effectiveness. Antibody-drug conjugates (ADCs) represent an innovative new class of medicines with activity in gynecologic malignancies and distinct toxicity profiles attributable to ADC construction. Adverse event mitigation strategies, biomarker discovery, and sequencing are paramount in successfully exploiting the therapeutic window provided by these novel compounds. This review discusses the application of ADCs in gynecologic cancers, including the current FDA-approved drugs mirvetuximab soravtansine, tisotumab vedotin, and trastuzumab deruxtecan, as well as relevant ongoing clinical trials, including TROP2 ADCs.

CONCLUSIONS: This ITC found no significant difference in clinical outcomes between low- and high-dose bevacizumab combination therapy. Despite limitations of small sample size and heterogeneities, findings suggest that bevacizumab dose may not significantly impact ovarian cancer outcomes.

No abstract available

CONCLUSIONS: As the first study to simultaneously examine this broad range of indicators of reproductive health within a single sample, we highlight the substantial burden of poor reproductive health in England, with evident ethnic and financial inequalities.

No abstract available

No abstract available

No abstract available

No abstract available

No abstract available

CONCLUSIONS: Our ex vivo study suggests that propranolol can augment uterine activity by approximately 20%-25% when administered early during labor induction and augmentation. Clinical studies are warranted to determine the relevance of these findings in vivo.

OBJECTIVE: To ascertain the perspectives and recommendations of Black individuals on their experience of spontaneous preterm birth (sPTB) and its impact on maternal mental health (MMH).

No abstract available

No abstract available

No abstract available

OBJECTIVE: To assess early (7-10 days) and late (24-35 days) clinical and mycological cure rates associated with single or multiple-day topical or oral treatment of uncomplicated vulvovaginal candidiasis (VVC).

STUDY QUESTION: Is being born of a young mother associated with worse gynecologic health, as indicated by a bilateral oophorectomy or hysterectomy before age 40?

No abstract available

OBJECTIVES: To investigate further the incidence and types of fetal abnormality identified at a routine 36-week ultrasound examination, which had not been diagnosed in previous scans at 20 weeks and 12 weeks' gestation, and to report the fetal abnormalities that are diagnosed only postnatally.